Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
2017 1
2018 1
2020 1
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for metronidazole la sant
Your search for metronidazol-la-sant retrieved no results
Reducing the duration of antibiotic therapy in surgical patients through a specific nationwide antimicrobial stewardship program. A prospective, interventional cohort study.
Batlle M, Badia JM, Hernández S, Grau S, Padulles A, Boix-Palop L, Giménez-Pérez M, Ferrer R, Calbo E, Limón E, Pujol M, Horcajada JP; Members of the 7VINCut Study Group; VINCat Program. Batlle M, et al. Int J Antimicrob Agents. 2023 Nov;62(5):106943. doi: 10.1016/j.ijantimicag.2023.106943. Epub 2023 Aug 2. Int J Antimicrob Agents. 2023. PMID: 37541529 Free article.
Out of 5458 antibiotic prescriptions, the most frequently analysed drugs were piperacillin/tazobactam (21.7%), metronidazole (11.2%), amoxicillin/clavulanate (10.3%), meropenem (10.7%), ceftriaxone (9.3%) and ciprofloxacin (6.7%). ...
Out of 5458 antibiotic prescriptions, the most frequently analysed drugs were piperacillin/tazobactam (21.7%), metronidazole (11.2%), …
Late poor outcomes of Clostridioides difficile infections in oncological patients: A multicentre cohort study.
Calbo E, Hernández S, Sopena N, Castellá L, Lopez-Contreras J, Cuquet J, López-Sánchez M, Pérez R, Gudiol C, Coloma A, Marimón M, Espinach J, Andres M, Martos P, Carvalho Rodrigues G, Limón E. Calbo E, et al. J Infect Prev. 2023 Jul;24(4):182-186. doi: 10.1177/17571774231165410. Epub 2023 Mar 21. J Infect Prev. 2023. PMID: 37333870
In addition, oncological patients receiving chemotherapy (CT) presented higher recurrence rates (18.5% vs 9.8%, p = 0.049). Among oncological patients treated with metronidazole, those with active CT showed a higher rate of recurrence (35.3% vs 8.0% p = 0.04). ...Their ear …
In addition, oncological patients receiving chemotherapy (CT) presented higher recurrence rates (18.5% vs 9.8%, p = 0.049). Among oncologica …
Cheilitis granulomatosa treated with metronidazole.
Miralles J, Barnadas MA, de Moragas JM. Miralles J, et al. Dermatology. 1995;191(3):252-3. doi: 10.1159/000246556. Dermatology. 1995. PMID: 8534947
We report the case of a patient with CG who has successfully been treated with metronidazole....
We report the case of a patient with CG who has successfully been treated with metronidazole....
Analysis of Clinical Phenotypes through Machine Learning of First-Line H. pylori Treatment in Europe during the Period 2013-2022: Data from the European Registry on H. pylori Management (Hp-EuReg).
Nyssen OP, Pratesi P, Spínola MA, Jonaitis L, Pérez-Aísa Á, Vaira D, Saracino IM, Pavoni M, Fiorini G, Tepes B, Bordin DS, Voynovan I, Lanas Á, Martínez-Domínguez SJ, Alfaro E, Bujanda L, Pabón-Carrasco M, Hernández L, Gasbarrini A, Kupcinskas J, Lerang F, Smith SM, Gridnyev O, Leja M, Rokkas T, Marcos-Pinto R, Meštrović A, Marlicz W, Milivojevic V, Simsek H, Kunovsky L, Papp V, Phull PS, Venerito M, Boyanova L, Boltin D, Niv Y, Matysiak-Budnik T, Doulberis M, Dobru D, Lamy V, Capelle LG, Nikolovska Trpchevska E, Moreira L, Cano-Català A, Parra P, Mégraud F, O'Morain C, Ortega GJ, Gisbert JP, On Behalf Of The Hp-EuReg Investigators. Nyssen OP, et al. Antibiotics (Basel). 2023 Sep 10;12(9):1427. doi: 10.3390/antibiotics12091427. Antibiotics (Basel). 2023. PMID: 37760723 Free PMC article.
The highest effectiveness (95%) was achieved in 2022, mostly in Spain (81%), with the bismuth-quadruple therapy, including the single-capsule (64%) and the concomitant treatment with clarithromycin-amoxicillin-metronidazole/tinidazole (34%) with 10 (69%) and 14 (32%) days. …
The highest effectiveness (95%) was achieved in 2022, mostly in Spain (81%), with the bismuth-quadruple therapy, including the single-capsul …
High Effectiveness of a 14-Day Concomitant Therapy for Helicobacter pylori Treatment in Primary Care. An Observational Multicenter Study.
Olmedo L, Azagra R, Aguyé A, Pascual M, Calvet X, Gené E. Olmedo L, et al. J Clin Med. 2020 Jul 28;9(8):2410. doi: 10.3390/jcm9082410. J Clin Med. 2020. PMID: 32731455 Free PMC article.
A 14-day concomitant therapy (amoxicillin 1 g, clarithromycin 500 mg and metronidazole 500 mg plus omeprazole 20 mg, all drugs administered twice daily) was prescribed. ...
A 14-day concomitant therapy (amoxicillin 1 g, clarithromycin 500 mg and metronidazole 500 mg plus omeprazole 20 mg, all drugs admini …
Bismuth-based quadruple therapy following H. pylori eradication failures: a multicenter study in clinical practice.
Zullo A, De Francesco V, Bellesia A, Vassallo R, D'Angelo A, Scaccianoce G, Sacco R, Bresci G, Eramo A, Tanzilli A, Ridola L, Alvaro D, Londoni C, Brambilla G, Manta R, Di Ciaula A, Portincasa P. Zullo A, et al. J Gastrointestin Liver Dis. 2017 Sep;26(3):225-229. doi: 10.15403/jgld.2014.1121.263.zul. J Gastrointestin Liver Dis. 2017. PMID: 28922433 Free article.
Probiotic supplementation with Lactobacillus plantarum and Pediococcus acidilactici for Helicobacter pylori therapy: A randomized, double-blind, placebo-controlled trial.
McNicholl AG, Molina-Infante J, Lucendo AJ, Calleja JL, Pérez-Aisa Á, Modolell I, Aldeguer X, Calafat M, Comino L, Ramas M, Callejo Á, Badiola C, Serra J, Gisbert JP. McNicholl AG, et al. Helicobacter. 2018 Oct;23(5):e12529. doi: 10.1111/hel.12529. Epub 2018 Aug 23. Helicobacter. 2018. PMID: 30141228 Clinical Trial.